Company Analysis
Sign in

Pliant Therapeutics, Inc. (PLRX)

Nasdaq: PLRX · Pharmaceutical Preparations · South San Francisco, CA · filing with the SEC since 2018
Full chart Alerts Compare
Grade4.7
◀ Past 4.4● Present 5.4▶ Future 4.3
4 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Income statement, as filed

In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.
Income statement, by fiscal year, newest first
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period endingDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019
Report filedMar 11, 2026Mar 3, 2025Feb 27, 2024Mar 9, 2023Mar 1, 2022Mar 16, 2021·
Revenue001,5809,6857,57241,81757,052
Research and development109,157169,310127,79796,93677,54966,19347,353
General and administrative47,21659,05557,92839,94927,55817,26910,930
Total operating expenses156,373228,365185,725136,885105,10783,46258,283
Operating income-156,373-228,365-184,145-127,200-97,535-41,645-1,231
Interest expense2,5593,0241,2677910··
Interest and investment income·····478816
Other income (expense), net·····-366-216
Income tax expense0000000
Net income including non-controlling interests····-97,263-41,533-631
Net income-149,344-210,304-161,336-123,321-97,263-41,533-631
Net income to common shareholders···-123,321-97,263-41,533-6,856
Earnings per share, basic-2.43-3.47-2.75-2.94-2.71-1.95-4.22
Earnings per share, diluted-2.43-3.47-2.75-2.94-2.71-1.95-4.22
Weighted average shares, basic61,366,88760,538,63958,719,08342,015,90835,846,42121,344,2361,623,358
Weighted average shares, diluted61,366,88760,538,63958,719,08342,015,90835,846,42121,344,2361,623,358
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it soldus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Research and development spent on inventing what it sells nextus-gaap:ResearchAndDevelopmentExpense
General and administrative the cost of running the company itselfus-gaap:GeneralAndAdministrativeExpense
Total operating expenses the running costs togetherus-gaap:OperatingExpenses
Operating income profit from running the business, before interest and taxus-gaap:OperatingIncomeLoss
Interest expense what its borrowing costus-gaap:InterestExpenseNonoperating
us-gaap:InterestExpense
Interest and investment income what its cash and investments earnedus-gaap:InvestmentIncomeInterest
Other income (expense), net gains and costs outside the businessus-gaap:OtherNonoperatingIncomeExpense
Income tax expense tax charged on the period's profitus-gaap:IncomeTaxExpenseBenefit
Net income including non-controlling interests the whole group's profit, minority holders' share includedus-gaap:ProfitLoss
Net income the profit or loss that belongs to the company's shareholdersus-gaap:NetIncomeLoss
Net income to common shareholders what is left for common shareholdersus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Earnings per share, basic net income per share outstandingus-gaap:EarningsPerShareBasic
Earnings per share, diluted net income per share, counting every share that could be issuedus-gaap:EarningsPerShareDiluted
Weighted average shares, basic the average count of shares outstandingus-gaap:WeightedAverageNumberOfSharesOutstandingBasic
Weighted average shares, diluted the average count with every share that could be issuedus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
SI Assistanton PLRX · research, not advice